Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 1616-1620 |
Seitenumfang | 5 |
Fachzeitschrift | Allergy: European Journal of Allergy and Clinical Immunology |
Jahrgang | 77 |
Ausgabenummer | 5 |
DOIs | |
Publikationsstatus | Veröffentlicht - Mai 2022 |
Zugriff auf Dokument
Andere Dateien und Links
Dieses zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
in: Allergy: European Journal of Allergy and Clinical Immunology, Jahrgang 77, Nr. 5, 05.2022, S. 1616-1620.
Publikation: Beitrag in Fachzeitschrift (peer-reviewed) › Brief/kurzer Abriss
TY - JOUR
T1 - Omicron
T2 - A SARS-CoV-2 variant of real concern
AU - Gattinger, Pia
AU - Tulaeva, Inna
AU - Borochova, Kristina
AU - Kratzer, Bernhard
AU - Trapin, Doris
AU - Kropfmüller, Anna
AU - Pickl, Winfried F
AU - Valenta, Rudolf
N1 - Funding Information: This study was supported by grants from Österreichische Forschungsförderungsgesellschaft, Grant number: 35721032; Austrian Science Fund, Grant number: DK-W1248; Viravaxx AG; Medizinisch-Wissenschaftlichen Fonds des Bürgermeisters der Bundeshauptstadt Wien, Grant numbers: COVID001 and COVID006. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We wish to acknowledge the help of Doris Werjant-Locmele and Anna Guentcheva regarding the recruitment and administration of study subjects. We are grateful to all individuals who participated in our study. Funding Information: This study was supported by grants from Österreichische Forschungsförderungsgesellschaft, Grant number: 35721032; Austrian Science Fund, Grant number: DK‐W1248; Viravaxx AG; Medizinisch‐Wissenschaftlichen Fonds des Bürgermeisters der Bundeshauptstadt Wien, Grant numbers: COVID001 and COVID006. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding Information: Rudolf Valenta has received research grants from HVD Life‐Sciences, Vienna, Austria, WORG Pharmaceuticals, Hangzhou, China and from Viravaxx AG, Vienna, Austria. He serves as consultant for Viravaxx AG and WORG Pharmaceuticals. The other authors have no conflict of interest to declare.
PY - 2022/5
Y1 - 2022/5
KW - COVID-19
KW - Humans
KW - Mutation
KW - SARS-CoV-2
KW - Spike Glycoprotein, Coronavirus
UR - http://www.scopus.com/inward/record.url?scp=85125399950&partnerID=8YFLogxK
U2 - 10.1111/all.15264
DO - 10.1111/all.15264
M3 - Letter/short communication
C2 - 35188670
SN - 0105-4538
VL - 77
SP - 1616
EP - 1620
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 5
ER -